Evaxion Biotech (EVAX) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Evaxion Biotech A/S has entered into a significant option and license agreement with Merck Sharp & Dohme LLC, with the aim of leveraging Evaxion’s AI-driven vaccine antigen prediction technologies. The collaboration is set to advance the development and commercialization of next-generation immunotherapies and vaccines, particularly focusing on antigens for bacterial species in the genus Neisseria. This partnership marks a strategic move for both companies in their pursuit to innovate and deliver cutting-edge solutions in the pharmaceutical sector.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
